Search

Displaying results 3691 - 3700 of 4539 in total
  1. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.

  2. Drug

    Alaproclate

    go.drugbank.com/drugs/DB13233
    Experimental

    Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s.

  3. Drug

    Penimepicycline

    go.drugbank.com/drugs/DB13264
    Experimental

    It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].

  4. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists.

  5. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.

  6. Drug

    QR-334

    go.drugbank.com/drugs/DB05473
    Experimental

    Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. No pharmaceutical interventions currently exist to treat sialorrhea.

  7. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name _Kanarb_ by Boryung Pharmaceuticals.

  8. Drug

    Ornithine

    go.drugbank.com/drugs/DB00129
    ApprovedInvestigationalNutraceutical

    Produced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine. L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine.

  9. Drug

    Testolactone

    go.drugbank.com/drugs/DB00894
    ApprovedWithdrawn

    An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.

  10. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. … Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine.